About Us

We were incorporated in 2009 in the state of California as a subsidiary of BioTime, Inc. Our mission is to develop novel products for the diagnosis and treatment of cancer based on embryonic stem cell-derived technology in order to improve both the quality and length of life of cancer patients...

BioTime Acquires Assets of Cell Targeting, Inc.
posted on January 28th, 2010

BioTime Acquires Assets of Cell Targeting, Inc.   BioTime, Inc. (NYSE Amex:BTX) today announced that it has acquired substantially all the assets of Cell Targeting, Inc. (CTI), a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine. The technology acquired from CTI uses peptides selected for their ability to adhere to diseased tissues. By coating [...]

BioTime Subsidiary OncoCyte Corporation Receives Second $2,000,000 Equity Tranche; BioTime Plans Additional $2,250,000 Investment
posted on January 7th, 2010

BioTime Subsidiary OncoCyte Corporation Receives Second $2,000,000 Equity Tranche; BioTime Plans Additional $2,250,000 Investment 1/7/2010 10:00:00 AM   BioTime, Inc. (NYSE Amex:BTIM) announced that its subsidiary OncoCyte Corporation has completed the funding of the second tranche of a private equity offering through the sale of 3,000,000 shares of OncoCyte common stock for $2,000,000 to a [...]